The Montreal Clinical Research Institute (IRCM) is proud to announce the launch of the RNA Therapy Development and Production Network, announced today by CQDM.
Led by the IRCM, this ambitious initiative will draw on three platforms: the Sidney-Altman RNA Therapeutics Hub at the IRCM, the RNomics Platform at the Université de Sherbrooke and the Therapeutic Messenger RNA Platform at McGill University's RNA Sciences Centre.
Thus, thanks to the power of collaboration and cutting-edge expertise, the RNA Therapy Development and Production Network will offer a complete range of services, from the initial design of RNA therapies to their production and validation on a preclinical scale. These services will be made available to scientists in both academia and industry, in a synergistic effort to accelerate the development of the most promising RNA therapies and bring them to maturity.
“At the IRCM, we believe in collaboration and have experienced how it fosters scientific excellence, leading to new therapies,” said Dr. Jean-François Côté, President and Scientific Director of the IRCM. “Being at the forefront of the RNA field in Quebec, it was only natural for our institute to initiate and propel this project, whose potential is simply inestimable for tomorrow's medicine."
The RNA Therapy Development and Production Network is one of the key initiatives of AReNa, a mobilizing project on RNA-based therapies. Announced on April 30, by the CQDM, mandated by the MEIE, AReNa aims to strengthen the RNA-based therapy ecosystem in Quebec and propel the province to world leadership in this field.
